000 | 01185 a2200349 4500 | ||
---|---|---|---|
005 | 20250513061100.0 | ||
264 | 0 | _c19930211 | |
008 | 199302s 0 0 eng d | ||
022 | _a0025-7125 | ||
024 | 7 |
_a10.1016/s0025-7125(16)30278-4 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aCaroff, S N | |
245 | 0 | 0 |
_aNeuroleptic malignant syndrome. _h[electronic resource] |
260 |
_bThe Medical clinics of North America _cJan 1993 |
||
300 |
_a185-202 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Review | ||
650 | 0 | 4 | _aAge Factors |
650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
650 | 0 | 4 |
_aDantrolene _xtherapeutic use |
650 | 0 | 4 | _aDiagnosis, Differential |
650 | 0 | 4 |
_aDopamine Agents _xtherapeutic use |
650 | 0 | 4 | _aElectric Stimulation Therapy |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aNeuroleptic Malignant Syndrome _xdiagnosis |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRecurrence |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 | _aSex Factors |
700 | 1 | _aMann, S C | |
773 | 0 |
_tThe Medical clinics of North America _gvol. 77 _gno. 1 _gp. 185-202 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0025-7125(16)30278-4 _zAvailable from publisher's website |
999 |
_c8092816 _d8092816 |